EB612, a first-in-class long-acting PTH(1-34) oral peptide for hypoparathyroidism, produced robust bioavailability and sustained increases in calcium across three preclinical models; IND is expected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results